FDA Brief

Warning letters Drugs

FDA warning letter to

Americo F. Padilla, M.D.

High riskIssued Mar 25, 2025Posted Mar 25, 2025Center for Drug Evaluation and Research (CDER)

FDA warns clinical investigator Americo F. Padilla, M.D. over failing to obtain parental consent before enrolling pediatric subjects in drug trials.

What happened

FDA inspected Dr. Padilla’s clinical site from February 1 to February 16, 2024, under its Bioresearch Monitoring Program and reviewed two investigational drug studies. FDA found that two pediatric subjects were enrolled in a trial without permission from a parent or guardian; a sibling signed for one subject and an uncle signed for the other, though neither was the parent or guardian. Actual parental permission was obtained about 10 months and about 9 months later, and FDA said the response did not give enough detail about corrective actions.

What FDA found

  1. Failed to obtain legally effective informed consent before involving human subjects in research.

    21 CFR 50.20; 21 CFR 312.60
  2. Failed to document informed consent with an IRB-approved written form signed and dated by the subject or legally authorized representative.

    21 CFR 50.27
  3. For a pediatric trial with greater than minimal risk and prospect of direct benefit, failed to make adequate provisions for child assent and parent or guardian permission.

    21 CFR 50.52; 21 CFR 50.55
  4. Enrolled two pediatric subjects without parent or guardian permission; a sibling and an uncle signed the consent form even though neither was the parent or guardian.

    21 CFR 50.27; 21 CFR 50.55(f)
  5. Obtained actual parental permission only about 10 months and about 9 months after the two subjects were enrolled.

    21 CFR 50.20; 21 CFR 50.27

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations and provide sufficient details about corrective actions; failure to adequately address the matter may lead to regulatory action.

Who should pay attention

  • clinical investigators running pediatric trials
  • IRBs and research sites
  • sponsors and CROs overseeing investigator sites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  4. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk